Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
dc.contributor.author | Grivas, Petros | |
dc.contributor.author | Mortazavi, Amir | |
dc.contributor.author | Picus, Joel | |
dc.contributor.author | Hahn, Noah M. | |
dc.contributor.author | Milowsky, Matthew I. | |
dc.contributor.author | Hart, Lowell L. | |
dc.contributor.author | Alva, Ajjai | |
dc.contributor.author | Bellmunt, Joaquim | |
dc.contributor.author | Pal, Sumanta K. | |
dc.contributor.author | Bambury, Richard M. | |
dc.contributor.author | O’donnell, Peter H. | |
dc.contributor.author | Gupta, Sumati | |
dc.contributor.author | Guancial, Elizabeth A. | |
dc.contributor.author | Sonpavde, Guru P. | |
dc.contributor.author | Faltaos, Demiana | |
dc.contributor.author | Potvin, Diane | |
dc.contributor.author | Christensen, James G. | |
dc.contributor.author | Chao, Richard C. | |
dc.contributor.author | Rosenberg, Jonathan E. | |
dc.date.accessioned | 2019-02-12T20:25:04Z | |
dc.date.available | 2020-04-01T15:06:25Z | en |
dc.date.issued | 2019-02-15 | |
dc.identifier.citation | Grivas, Petros; Mortazavi, Amir; Picus, Joel; Hahn, Noah M.; Milowsky, Matthew I.; Hart, Lowell L.; Alva, Ajjai; Bellmunt, Joaquim; Pal, Sumanta K.; Bambury, Richard M.; O’donnell, Peter H. ; Gupta, Sumati; Guancial, Elizabeth A.; Sonpavde, Guru P.; Faltaos, Demiana; Potvin, Diane; Christensen, James G.; Chao, Richard C.; Rosenberg, Jonathan E. (2019). "Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes." Cancer 125(4): 533-540. | |
dc.identifier.issn | 0008-543X | |
dc.identifier.issn | 1097-0142 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/147860 | |
dc.description.abstract | BackgroundThe authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a singleâ arm, openâ label phase 2 study.MethodsEligible patients with platinumâ treated, advanced/metastatic disease received oral mocetinostat (at a dose of 70 mg 3 times per week [TIW] escalating to 90 mg TIW) in 28â day cycles in a 3â stage study (ClinicalTrials.gov identifier NCT02236195). The primary endpoint was the objective response rate.ResultsGenomic testing was feasible in 155 of 175 patients (89%). Qualifying tumor mutations were CREBBP (15%), EP300 (8%), and both CREBBP and EP300 (1%). A total of 17 patients were enrolled into stage 1 (the intentâ toâ treat population); no patients were enrolled in subsequent stages. One partial response was observed (11% [1 of 9 patients; the population that was evaluable for efficacy comprised 9 of the 15 planned patients]); activity was deemed insufficient to progress to stage 2 (null hypothesis: objective response rate of â ¤15%). All patients experienced â ¥1 adverse event, most commonly nausea (13 of 17 patients; 77%) and fatigue (12 of 17 patients; 71%). The median duration of treatment was 46 days; treatment interruptions (14 of 17 patients; 82%) and dose reductions (5 of 17 patients; 29%) were common. Mocetinostat exposure was lower than anticipated (doseâ normalized maximum serum concentration [Cmax] after TIW dosing of 0.2 ng/mL/mg).ConclusionsTo the authorsâ knowledge, the current study represents the first clinical trial using genomicâ based selection to identify patients with urothelial cancer who are likely to benefit from selective histone deacetylase inhibition. Mocetinostat was associated with significant toxicities that impacted drug exposure and may have contributed to modest clinical activity in these pretreated patients. The efficacy observed was considered insufficient to warrant further investigation of mocetinostat as a single agent in this setting.After the genomicâ based selection of patients with urothelial cancer with inactivating mutations/deletions in the histone acetyltransferase genes CREBBP and/or EP300, singleâ agent mocetinostat appears to be associated with significant toxicities that limit drug exposure. This may have contributed to the limited activity noted in the current phase 2 study (response rate of 11%) among heavily pretreated patients with platinumâ refractory disease. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | urothelial carcinoma | |
dc.subject.other | CREB binding protein (CREBBP) | |
dc.subject.other | E1A binding protein p300 (EP300) | |
dc.subject.other | histone deacetylase | |
dc.subject.other | mocetinostat | |
dc.title | Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/147860/1/cncr31817_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/147860/2/cncr31817.pdf | |
dc.identifier.doi | 10.1002/cncr.31817 | |
dc.identifier.source | Cancer | |
dc.identifier.citedreference | Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23: 4225 â 4231. | |
dc.identifier.citedreference | Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017; 71: 96 â 108. | |
dc.identifier.citedreference | Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumâ containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27: 4454 â 4461. | |
dc.identifier.citedreference | Choueiri TK, Ross RW, Jacobus S, et al. Doubleâ blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumâ pretreated metastatic urothelial cancer. J Clin Oncol. 2012; 30: 507 â 512. | |
dc.identifier.citedreference | Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTEâ 045 Investigators. Pembrolizumab as secondâ line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 1015 â 1026. | |
dc.identifier.citedreference | Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20: 3898 â 3941. | |
dc.identifier.citedreference | Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014; 5: 265 â 296. | |
dc.identifier.citedreference | Poyet C, Jentsch B, Hermanns T, et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol. 2014; 14: 10. | |
dc.identifier.citedreference | Pinkerneil M, Hoffmann MJ, Deenen R, et al. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol Cancer Ther. 2016; 15: 299 â 312. | |
dc.identifier.citedreference | Suraweera A, Oâ Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018; 8: 92. | |
dc.identifier.citedreference | Zhou N, Moradei O, Raeppel S, et al. Discovery of Nâ (2â aminophenyl)â 4â [(4â pyridinâ 3â ylpyrimidinâ 2â ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem. 2008; 51: 4072 â 4075. | |
dc.identifier.citedreference | Batlevi CL, Crump M, Andreadis C, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017; 28: 2047 â 2049. | |
dc.identifier.citedreference | Blum KA, Advani A, Fernandez L, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 2009; 147: 507 â 514. | |
dc.identifier.citedreference | Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkinâ s lymphoma: an openâ label, singleâ arm, phase 2 trial. Lancet Oncol. 2011; 12: 1222 â 1228. | |
dc.identifier.citedreference | Duex JE, Swain KE, Dancik GM, et al. Functional impact of chromatin remodeling gene mutations and predictive signature for therapeutic response in bladder cancer. Mol Cancer Res. 2018; 16: 69 â 77. | |
dc.identifier.citedreference | Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinumâ containing regimens. J Clin Oncol. 2010; 28: 1850 â 1855. | |
dc.identifier.citedreference | Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507: 315 â 322. | |
dc.identifier.citedreference | Robertson AG, Kim J, Alâ Ahmadie H, et al. Comprehensive molecular characterization of muscleâ invasive bladder cancer. Cell. 2017; 171: 540 â 556.e525. | |
dc.identifier.citedreference | Wang F, Marshall CB, Ikura M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci. 2013; 70: 3989 â 4008. | |
dc.identifier.citedreference | Boumber Y, Younes A, Garciaâ Manero G. Mocetinostat (MGCD0103): a review of an isotypeâ specific histone deacetylase inhibitor. Expert Opin Investig Drugs. 2011; 20: 823 â 829. | |
dc.identifier.citedreference | Chan E, Chiorean EG, Oâ Dwyer PJ, et al. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemother Pharmacol. 2018; 81: 355 â 364. | |
dc.identifier.citedreference | Schneider BJ, Kalemkerian GP, Bradley D, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs. 2012; 30: 249 â 257. | |
dc.identifier.citedreference | Munster PN, Marchion D, Thomas S, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009; 101: 1044 â 1050. | |
dc.identifier.citedreference | Cheung EM, Quinn DI, Tsaoâ Wei DD, et al. Phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced transitional cell urothelial cancer after platinumâ based therapy. J Clin Oncol. 2008; 26 (suppl 15): 16058. | |
dc.identifier.citedreference | Pili R, Salumbides B, Zhao M, et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13â cis retinoic acid in patients with solid tumours. Br J Cancer. 2012; 106: 77 â 84. | |
dc.identifier.citedreference | Gupta S, Albertson DJ, Parnell T, et al. Clinical and translational investigation of panâ HDAC inhibition in advanced urothelial carcinoma. J Clin Oncol. 2017; 35 (suppl 6): 379. | |
dc.identifier.citedreference | Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large Bâ cell lymphoma. Blood. 2016; 128: 185 â 194. | |
dc.identifier.citedreference | Falkenberg KJ, Gould CM, Johnstone RW, Simpson KJ. Genomeâ wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. Sci Data. 2014; 1: 140017. | |
dc.identifier.citedreference | Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PDâ 1 ligands in melanoma and augments immunotherapy with PDâ 1 blockade. Cancer Immunol Res. 2015; 3: 1375 â 1385. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.